Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

16.43 -0.37 (-2.20%)
Streaming Delayed Price Updated: 10:29 AM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 627,149
Open 16.89
Bid (Size) 16.42 (500)
Ask (Size) 16.44 (300)
Prev. Close 16.80
Today's Range 16.43 - 17.00
52wk Range 10.41 - 43.92
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
My Top 3 Biotech Stocks for May 2026 ↗
As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire

Performance

YTD
-22.9%
-22.9%
1 Month
-21.7%
-21.7%
3 Month
-9.3%
-9.3%
6 Month
-13.1%
-13.1%
1 Year
-57.2%
-57.2%

More News

Read More
News headline image
Sarepta (SRPT) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Sarepta Therapeutics (NASDAQ:SRPT) Q1 2026 Earnings Beat Overshadowed by Revenue Dip ↗
Via Chartmill
Topics Earnings
News headline image
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
Via Investor Brand Network
Topics Artificial Intelligence
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
Via Investor Brand Network
News headline image
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
From BioMedWire
Via GlobeNewswire
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
Via MarketMinute
Topics Economy Intellectual Property Stocks
News headline image
Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics
Via MarketMinute
News headline image
Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
Via MarketMinute
News headline image
The RNA Renaissance: Decoding Sarepta Therapeutics’ 34% Surge and the Future of Precision Medicine
Via Finterra
Topics Retirement
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Wednesday's session: top gainers and losers ↗
Via Chartmill
Which stocks are gapping on Wednesday? ↗
Via Chartmill
News headline image
Sarepta Therapeutics (SRPT) at a Crossroads: A 2026 Deep Dive into the Future of Genetic Medicine
Via Finterra
Topics Economy Intellectual Property Retirement
News headline image
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
2 Beaten-Down Stocks That Still Aren't Worth Buying ↗
Via The Motley Fool
Topics Cannabis
News headline image
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study ↗
Via Stocktwits
Topics Death
News headline image
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
From Sarepta Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?
Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?
The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market
What is the current price of Sarepta Therapeutics, Inc. - Common Stock?
The current price of Sarepta Therapeutics, Inc. - Common Stock is 16.43
When was Sarepta Therapeutics, Inc. - Common Stock last traded?
The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 05/26/26 10:29 AM ET
What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?
The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 1.53B
How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?
Sarepta Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.